Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–311 of 311 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Overweight Subjects Clear all

Conditions: Breast Cancer Survivors
Interventions: Aspirin, Omega 3 FFA; Drug · Dietary Supplement
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity
Interventions: NO-13065, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Factory, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: ALT-801, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 13
States / cities: Montclair, California • Sacramento, California • Miami Lakes, Florida + 7 more

Conditions: Obesity, Insulin Resistance
Interventions: MICARDIS® (telmisartan); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Westlake Village, California + 5 more

Conditions: Healthy
Interventions: LY3463251, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets); Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Blood Pressure
Interventions: VI-0521, Phentermine, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 28
States / cities: Anniston, Alabama • Mobile, Alabama • Lincoln, California + 25 more

Conditions: Obesity, Type 2 Diabetes, Cardiovascular Diseases, Acute Exercise
Interventions: Acute exercise; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC9204-1706, Placebo (NNC9204-1706); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psoriasis, Obesity
Interventions: Adipose tissue biopsy (fat biopsy); Procedure
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: AZD6234, Placebo, Acetaminophen; Drug · Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 67
States / cities: Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more

Conditions: Obesity
Interventions: Metformin, VI-0521, Sitagliptan, Probenecid; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
Interventions: FT-4101, FT-4101 placebo, Deuterated Water; Drug · Other
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Chula Vista, California • Montclair, California

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC9204-0530, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Insulin Resistance, Obesity
Interventions: Not listed
Lead sponsor: Rockefeller University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: AMG 171, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Anaheim, California • Tustin, California • Miami, Florida

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC9204-1177, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prader-Willi Syndrome
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Irvine, California • Gainesville, Florida • Kansas City, Kansas + 2 more

Conditions: Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions: Olmesartan medoxomil, Losartan potassium, Atenolol; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more

Conditions: Metabolism and Nutrition Disorder, Obesity, Obstructive Sleep Apnoea
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Glendale, California • Oceanside, California • Orange, California + 30 more

Conditions: Healthy
Interventions: Voriconazole low dose, Voriconazole high dose; Drug
Lead sponsor: Manjunath Prakash Pai; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Obesity
Interventions: sibutramine hydochloride monohydrate; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: North Chicago, Illinois

Search by objective public record fields.

Impact of COX2 on Sera Biomarkers From Obese Subjects

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

A Study of LY3463251 in Healthy Participants

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

Epigenetic Effects of a Single Bout of Exercise on Cardiovascular Risk Factors and the Metabolome

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Pharmacokinetics of Voriconazole in Obese Subjects

A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.